- RecruitingPHASE3
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
This study looks at two medicines, ivosidenib and azacitidine, for a blood condition called myelodysplastic syndromes (MDS). It's for people with a specific gene change (IDH1 mutation) who haven't had certain treatments before. The aim is to see which medicine works best.
For: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS)United States · Australia · Brazil - RecruitingPHASE3
Personalized Medicine for Advanced Biliary Cancer Patients
This study looks at whether adding a special "targeted" drug after initial treatment for advanced bile duct cancer works better than continuing standard treatment. It customises treatment based on your tumour's unique features.
For: Biliary Tract NeoplasmsBelgium · France · United Kingdom